
Plasma from coronavirus survivors, "only" option before the vaccine
2 April 2020
They identify a drug capable of blocking the coronavirus in early stages
3 April 2020
The health center, through the IIS Aragón, will collaborate in the 'Solidaridad' clinical trial to obtain evidence on the effectiveness of treatments in patients with COVID-19.
The principal investigator of the study is Dr. José Ramón Paño, from the Infectious Diseases Service.
The Lozano Blesa University Clinical Hospital in Zaragoza, through the Aragón Health Research Institute (IIS Aragón), is one of the ten hospitals in Spain that will participate in the 'Solidarity' clinical trial, an initiative of the World Health Organization (WHO). The principal investigator of the study is Dr. José Ramón Paño, from the Infectious Diseases Service and researcher at IIS Aragón.
This is a multicenter trial in which almost 50 countries will collaborate with the aim of evaluating and obtaining scientific evidence on the effectiveness of treatments in hospitalized patients who have tested positive for coronavirus since, until now, after several weeks of the pandemic, the studies carried out were not controlled.
Patients who agree to participate in the trial will receive randomized treatment from among the five available regimens. They must be over 18 years of age and have laboratory-confirmed positive COVID-19, in addition to not having previously received any of the study medications and not having contraindications for them. Thus, a group of patients will receive the conventional treatment that is being given to all patients with COVID-19 who come to the hospital. A second group will be treated with the antiviral “remdesivir”, produced by the company Gilead and used against Ebola. The third group will receive a combination of “lopinavir” and “ritonavir”, commonly used for HIV carriers, while the fourth will add to these two antiretrovirals the use of “interferon beta”, used against multiple sclerosis. Finally, the fifth group of patients will receive “chloroquine”, a drug used against malaria and rheumatism.
The results will be examined by a global data and safety monitoring committee of experts to see if any of the treatments slow the progression or improve survival of the disease. WHO will encrypt and maintain patient information securely, so patient data will be completely anonymous and no identifiable patient details will appear in presentations or publications.
“We are very proud that Aragonese scientists participate in the trial that the WHO is going to carry out on Covid-19 in 50 countries,” said Ángel Lanas, scientific director of the IIS Aragón.
Aragon Health Research Institute
The IIS Aragón is the Health Research Institute of the hospital complex formed by the Lozano Blesa and Miguel Servet Teaching and University Hospitals and Primary Health Care. The University of Zaragoza and the Aragonese Institute of Health Sciences are associated with this hospital complex through different legal instruments.
The objectives of the IIS Aragón are to bring together basic and applied, clinical and health services research; create a quality research, care and teaching environment to which health professionals, training specialists and postgraduate and undergraduate students are exposed, as well as constitute the ideal place for attracting talent and the location of large scientific facilities. technological.